WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release drug delivery products for treatment of back-of-the-eye
diseases, today announced that its financial results for the first
quarter of fiscal year 2014 will be released after the market close on
Tuesday, November 12, 2013, followed the same day by a conference call
and live webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (877) 312-7507 from the
U.S. and Canada, or (631) 813-4828 from international locations. A live
webcast will be available on the Investor Relations section of the
corporate website at http://www.psivida.com.
A replay of the call will be available beginning November 12, 2013 at
approximately 7:30 p.m. ET and ending on November 19, 2013. The replay
may be accessed by dialing (855) 859-2056 within the U.S. and Canada or
(404) 537-3406 from international locations, Conference ID Number:
97230646. A replay of the webcast will also be available on the
corporate website during that time.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™,
including Tethadur™. The injectable, sustained release micro-insert
ILUVIEN® for the treatment of chronic Diabetic Macula Edema (DME)
considered insufficiently responsive to available therapies, licensed to
Alimera Sciences, Inc., is marketed in the U.K. and Germany and has also
received marketing authorization in Austria, France, Portugal, and Spain
and is awaiting authorization in Italy. pSivida has instituted the first
of two planned pivotal Phase III clinical trials for Medidur™ for the
treatment of posterior uveitis, a chronic back-of-the-eye disease. An
investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible micro-insert to treat glaucoma and ocular hypertension, a
product candidate on which Pfizer Inc. has an option. pSivida's
FDA-approved Retisert®, licensed to Bausch & Lomb Incorporated, provides
long-term, sustained drug delivery to treat posterior uveitis.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
Tel:
+1 (312) 943 1123
bjedynak@janispr.com
or
In
Australia:
pSivida Corp.
Brian Leedman
Vice President,
Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
Source: pSivida Corp.
News Provided by Acquire Media
